Latest Coronavirus: Paltrow’s San Francisco Goop Store Closes, Becoming the Last Victim of the City’s Retail

CureVac said it will gain European recognition despite the disappointing overall efficacy results of the coronary vaccine candidate, while the final analysis of its final phase trial shows 77% protection against serious diseases and full protection against hospitalization and death.

Earlier in June, shares of the German biopharmaceutical company fell by about 50 per cent when provisional data showed an overall efficiency of 47 per cent, far from the development of Moderna and BioNTech’s rival ribonucleic acid messenger (mRNA) owners.

A recent analysis by Nasdaq-listed CureVac showed a 48 percent effectiveness against Covid-19 against all seriousness, and 53% against mild illness. He said that in cases between the ages of 18 and 60, being more effective against serious illnesses led to the approval of his European CVnCoV vaccine.

“In this latest analysis, CVnCoV demonstrates the high value of public health when it protects participants in 18- to 60-year-old studies against hospitalization and death and 77 percent of moderate to severe diseases – an efficiency profile that we believe is an important contribution to the Covid-19 pandemic and to help spread the dynamic variant, ”said CEO Franz-Werner Haas.

CureVac has argued that the performance of the mRNA vaccine it is producing with the help of pharmaceutical giant Bayer was lower because it treated 15 different variants of the virus. About 86 percent of coronavirus cases at trial came from strains listed by the World Health Organization as a “variant of concern” or “variant of interest”. But recent research has shown even greater efficacy among other vaccines.

Haas said the CureVac trial, which looked at 40,000 subjects in Europe and Latin America, will also provide valuable data on coronavirus variants. Almost none of its subjects suffered from the original coronavirus strain, the company said, with about 11 percent fewer variants being studied.

Earlier this month, CureVac said tThe Financial Times could accept certain age groups, certain severity levels, or as a potential kick. He also stressed that the second-generation vaccine to combat the variants of viruses that are being developed with GlaxoSmithKline should not result in poor results from the original vaccine because it is designed differently.